Trials
2 active
16 in total · 2 in the EU
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “ISL/ULO fixed-dose combination 2 mg/200 mg oral tablet administered qw for 96 weeks”In the company’s words, NCT07266831 on ClinicalTrials.gov
- Tested for
- Human Immunodeficiency Virus Type 1 (HIV-1) Infection (2 trials)
- Main trialPhase 2/3
- “Researchers are looking for new ways to treat HIV-1 (Human Immunodeficiency Virus Type 1). The usual (standard) treatment for HIV-1 is antiretroviral therapy (ART), which includes taking medicines to lower the amount of HIV-1 in the body. Standard ART helps people live longer, but people must take up to 3 medicines up to twice a day. Standard ART may also cause other health problems. Researchers want to know if a study ART works as well as a standard ART to treat HIV-1. The study ART combines 2 medicines, islatravir and ulonivirine, and is taken once a week. The goals of this study are to…”In the company’s words, NCT07266831 on ClinicalTrials.gov
- Other names
- ISL · MK-8591
Other drugs for Human Immunodeficiency Virus Type 1 (HIV-1) Infection
- ACC017Jiangsu Aidea Pharmaceutical Group Co., Ltd. · Phase 3
- AlimatravirMerck & Co. · Phase 3
- UlonivirineMerck & Co. · Phase 2/3
- ISL/ULOMerck & Co. · Phase 2/3
- CabotegravirViiV Healthcare · Phase 3
- DOVATOViiV Healthcare · Phase 3
Coming up2
- 10 Aug 2027Phase 2 trial completes · ClinicalTrials.gov
- 1 Feb 2029Phase 2/3 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials16
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 2/3Recruiting | 1 Feb 2029 | A Clinical Study of Islatravir and Ulonivirine for People With HIV-1 Who Have Not Been Treated Before (MK-8591B-062) | |
| Phase 2Active, not recruiting | 10 Aug 2027 | A Study of Islatravir (ISL) and Ulonivirine (ULO) Once Weekly (QW) in Virologically Suppressed Adults With Human Immunodeficiency Virus Type 1 (HIV-1) (MK-8591B-060) | |
| Phase 3Completed | 21 Nov 2022 | Doravirine/Islatravir (DOR/ISL) in Heavily Treatment-Experienced (HTE) Participants for Human Immunodeficiency Virus Type 1 (HIV-1) Infection (MK-8591A-019) | |
| Phase 3Terminated | 18 Jul 2023 | Oral ISL QM as PrEP in Cisgender Women at High Risk for HIV-1 Infection (MK-8591-022) | |
| Phase 3Terminated | 4 Aug 2023 | Oral Islatravir (MK-8591) Once-Monthly as Preexposure Prophylaxis (PrEP) in Men and Transgender Women Who Are at High Risk for HIV-1 Infection (MK-8591-024) | |
| Phase 2Completed | 8 Mar 2021 | Islatravir (MK-8591) With Doravirine and Lamivudine in Participants Infected With Human Immunodeficiency Virus Type 1 (MK-8591-011) | |
| Phase 2Completed | 18 Mar 2022 | Safety and Pharmacokinetics of Oral Islatravir (MK-8591) Once Monthly in Participants at Low Risk of Human Immunodeficiency Virus 1 (HIV-1) Infection (MK-8591-016) | |
| Phase 2Withdrawn | 25 Mar 2024 | A Study of Islatravir (MK-8591) in Trans and Gender Diverse Participants (MK-8591-035) | |
| Phase 2Completed | 30 Jan 2025 | Dose Ranging, Switch Study of Islatravir (MK-8591) and Ulonivirine (MK-8507) Once-Weekly in Virologically-Suppressed Adults With Human Immunodeficiency Virus Type 1 (HIV-1) [MK-8591-013] | |
| Phase 2Withdrawn | 2 Oct 2025 | Radiopaque Matrix MK-8591 Implant in Participants at Low-Risk for Human Immunodeficiency Virus Type 1 (HIV-1) Infection (MK-8591-043) | |
| Phase 1Completed | 19 Oct 2020 | Pharmacokinetics of Islatravir in Participants With Severe Renal Impairment (MK-8591-026) | |
| Phase 1Completed | 9 Jul 2021 | Islatravir and Methadone Pharmacokinetics (MK-8591-029) | |
| Phase 1Completed | 13 Sep 2021 | Single-Dose Islatravir in Moderate Hepatic Impairment (MK-8591-030) | |
| Phase 1Completed | 15 Mar 2024 | A Study of Doravirine and Islatravir as a Single Entity or Combination Therapy and the Effect of Food in Healthy Adult Participants (MK-8591A-055) | |
| Phase 1Completed | 23 Jun 2024 | A Study of MK-8507 and Islatravir (MK-8591) in Healthy Adult Participants (MK-8507-016) | |
| Phase 1Completed | 14 Jul 2024 | A Clinical Study of Islatravir and Its Interaction With Lamivudine (MK-8591-058) |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026